Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
The Russian-made vaccine posts competitive phase III data – but not on the easily stored formulation.